Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism

Neuropathology and Applied Neurobiology

Volumn 39, Issue 2, 2013, Pages 132-143

  Annese, V ^a,b,c   Barcia, C ^a,b   Ros Bernal, F ^a,b   Gomez A ^a,b   Ros, C M ^a,b   De Pablos, V ^a,b   Fernandez Villalba E ^a,b   De Stefano, M E ^c,d   Herrero, M T ^a,b  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c Pasteur Institute   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Glial response; MPTP; Neurodegeneration; Oligodendrocytes; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CELL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CELL COUNT; CELL SIZE; CELL STRUCTURE; CELL TYPE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORPUS STRIATUM; GLIOSIS; INNERVATION; MALE; MOUSE; NONHUMAN; OLIGODENDROGLIA; OLIGODENDROGLIOSIS; PARKINSONISM; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA; TISSUE SECTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CYTOLOGY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; MACACA; NEOSTRIATUM; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; MACACA; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; OLIGODENDROGLIA; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

EID: 84873032684     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2012.01271.x     Document Type: Article

References (41)

1. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010; 16: 653-61
2. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67: 715-25
3. Tong J, Furukawa Y, Sherwin A, Hornykiewicz O, Kish SJ. Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain. Neurobiol Dis 2011; 41: 458-68
4. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann Neurol 1999; 46: 598-605
5. Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001; 106: 589-601
6. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909
7. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 1985; 82: 2173-7
8. Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, Johannessen JN. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 1991; 40: 133-58
9. Conforti L, Adalbert R, Coleman MP. Neuronal death: where does the end begin? Trends Neurosci 2007; 30: 159-66
10. Duda JE. Parkinson's disease: the life cycle of the dopamine neuron. Ann N Y Acad Sci 2003; 991: 1-360
11. Taveggia C, Feltri ML, Wrabetz L. Signals to promote myelin formation and repair. Nat Rev Neurol 2010; 6: 276-87
12. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-55
13. McTigue DM, Tripathi RB. The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem 2008; 107: 1-19
14. Levine JM, Reynolds R, Fawcett JW. The oligodendrocyte precursor cell in health and disease. Trends Neurosci 2001; 24: 39-47
15. Horner PJ, Power AE, Kempermann G, Kuhn HG, Palmer TD, Winkler J, Thal LJ, Gage FH. Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci 2000; 20: 2218-28
16. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A, Hirsch EC, Herrero MT. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004; 46: 402-9
17. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008; 23: 474-83
18. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97
19. Takagi S, Hayakawa N, Kimoto H, Kato H, Araki T. Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm 2007; 114: 1553-7
20. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/alphasynuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl) 2000; 99: 14-20
21. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007; 2: 141-51
22. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A 2010; 107: 20021-6
23. Di Monte DA, Wu EY, Langston JW. Role of astrocytes in MPTP metabolism and toxicity. Ann N Y Acad Sci 1992; 648: 219-28
24. Horton M, Rafay M, Del Bigio MR. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. J Child Neurol 2009; 24: 1543-6
25. Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, DiStefano PS. Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 1998; 43: 46-55
26. Lach B, Grimes D, Benoit B, Minkiewicz-Janda A. Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol (Berl) 1992; 83: 352-60
27. Galvin JE, Uryu K, Lee VM, Trojanowski JQ. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A 1999; 96: 13450-5
28. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002; 52: 205-10
29. Cochiolo JA, Ehsanian R, Bruck DK. Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: evidence of compensatory plasticity in nigrostriatal neurons. J Neurosci Res 2000; 59: 126-35
30. Pickel VM, Beckley SC, Joh TH, Reis DJ. Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res 1981; 225: 373-85
31. Smith Y, Bennett BD, Bolam JP, Parent A, Sadikot AF. Synaptic relationship between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey. J Comp Neurol 1994; 344: 1-19
32. Kung L, Force M, Chute DJ, Roberts RC. Immunocytochemical localization of tyrosine hydroxylase in the human striatum: a postmortem ultrastructural study. J Comp Neurol 1998; 390: 52-62
33. Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 2011; 34: 441-66
34. Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31: 535-61
35. Bozzali M, Wrabetz L. Axonal signals and oligodendrocyte differentiation. Neurochem Res 2004; 29: 979-88
36. Jessen KR, Mirsky R. Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia 2008; 56: 1552-65
37. Charles P, Hernandez MP, Stankoff B, Aigrot MS, Colin C, Rougon G, Zalc B, Lubetzki C. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc Natl Acad Sci U S A 2000; 20: 7585-90
38. Stankoff B, Demerens C, Goujet-Zalc C, Monge M, Peyron F, Mikoshiba K, Zalc B, Lubetzki C. Transcription of myelin basic protein promoted by regulatory elements in the proximal 5′ sequence requires myelinogenesis. Mult Scler 1996; 2: 125-32
39. Girolamo F, Strippoli M, Errede M, Benagiano V, Roncali L, Ambrosi G, Virgintino D. Characterization of oligodendrocyte lineage precursor cells in the mouse cerebral cortex: a confocal microscopy approach to demyelinating diseases. Ital J Anat Embryol 2010; 115: 95-102
40. Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002; 22: 2451-9
41. Solly SK, Thomas JL, Monge M, Demerens C, Lubetzki C, Gardinier MV, Matthieu JM, Zalc B. Myelin/oligodendrocyte glycoprotein (MOG) expression is associated with myelin deposition. Glia 1996; 18: 39-48